Review reveals gastrointestinal toxicity from immune checkpoint inhibitors and targeted therapies in cancer treatment, suggesting management strategies for oncologists.
Key Points
Colitis and diarrhoea are the most common gastrointestinal side effects of targeted therapies, limiting their use and patient care.
Anti-PD-1 and anti-CTLA-4 therapies frequently cause colitis similar to inflammatory bowel disease, suggesting serious adverse effects.
Comprehensive literature review assessed lower gastrointestinal toxicities associated with various cancer therapy classes, highlighting treatment management needs.
Understanding the gastrointestinal impacts of therapies may enhance patient management and optimize oncological outcomes.